紫杉醇(Paclitaxel) - 药物靶点：Tubulin_在研适应症：晚期胃癌，转移性胰腺腺癌，转移性乳腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

EmPAC、LDE-paclitaxel、NanoPac

+ [78]

靶点

Tubulin

作用方式

抑制剂

作用机制

微管蛋白抑制剂

治疗领域

肿瘤感染消化系统疾病+ [12]

在研适应症

晚期胃癌转移性胰腺腺癌转移性乳腺癌+ [215]

非在研适应症

异戊酸血症急性淋巴细胞白血病食管腺癌+ [206]

原研机构

National Institutes of Health

在研机构

National Cancer InstituteToLymph Inc.

NRG Oncology

+ [54]

非在研机构

The Gynecologic Oncology GroupHQ Specialty Pharma Corp.

Eli Lilly & Co.

+ [51]

权益机构

深圳市康哲药业有限公司

沈阳三生制药有限责任公司

Hanmi Pharmaceutical Co., Ltd.

+ [26]

最高研发阶段批准上市

首次获批日期

美国 (1992-12-29),

艾滋病相关性卡波西肉瘤乳腺癌卵巢癌

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS号33069-62-4

关联

2,845

项与紫杉醇相关的临床试验

NCT07346196

/ Not yet recruiting临床2期IIT

A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.

开始日期2027-02-07

申办/合作机构

The University of Chicago

NCT07281417

/ Recruiting临床2期IIT

Neoadjuvant Chemotherapy With or Without Cemiplimab (REGN2810) in Sinonasal Squamous Cell Carcinoma: A Randomized Phase 2 Study

This phase II trial compares the effect of chemotherapy (carboplatin and paclitaxel) with versus without cemiplimab given before surgery (neoadjuvant) in patients with sinonasal squamous cell cancer. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients with sinonasal squamous cell cancer is surgery followed by radiation therapy, with or without chemotherapy. Recently, some patients have also been treated with neoadjuvant chemotherapy before surgery. Adding cemiplimab to chemotherapy before surgery may be more effective at stopping the cancer from growing or spreading, compared to chemotherapy alone.

开始日期2026-11-24

申办/合作机构

National Cancer Institute

NCT07195734

/ Recruiting临床2期IIT

A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients With Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cisplatin for high risk patients, for the treatment of patients with PD-L1 positive head and neck squamous cell carcinoma that has come back and spread to nearby tissue or lymph nodes after a period of improvement (locally recurrent) or is persistent. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Salvage surgery is surgery that takes place to remove tumor tissue after a failure of other treatment. High risk patients also receive radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding chemotherapy or chemo-immunotherapy to standard salvage surgery may kill more tumor cells than salvage surgery alone in patients with PD-L1 positive locally recurrent or persistent head and neck squamous cell carcinoma.

开始日期2026-10-09

申办/合作机构

National Cancer Institute

100 项与紫杉醇相关的临床结果

登录后查看更多信息

100 项与紫杉醇相关的转化医学

登录后查看更多信息

100 项与紫杉醇相关的专利（医药）

登录后查看更多信息

52,111

项与紫杉醇相关的文献（医药）

2026-12-31·Future Science OA

Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer

Article

作者: Su, Zhimin ; Li, Zhiyong ; Shen, Feng ; Jiang, Jiana

OBJECTIVE:

We aim to compare the clinical efficacy and safety of albumin-bound paclitaxel (nab-PTX) (125 mg/m2, q2w) for two weeks and (125 mg/m2, d1, d8, q3w) for three weeks in the first-line treatment of advanced pancreatic cancer.

METHODS:

The medical records of patients with advanced pancreatic cancer who received nab-PTX for 2 weeks and 3 weeks, combined with gemcitabine, from July 2018 to January 2023, were retrospectively analyzed. The efficacy and adverse reactions of the two groups of patients were compared.

RESULT:

A total of 64 patients were included. The median progression-free survival (mPFS) of the 2-week group was 5.6 months, while the 3-week group was 7.8 months. The median overall survival (mOS) of the 2-week group was 14.0 months, while the 3-week group was 14.7 months. The multivariate analysis showed that a physical fitness status score of 0-1 was an independent factor with better OS, while metastatic sites ≥ 3 were related to poor OS. The incidence of leukopenia or neutropenia, neurotoxicity, fatigue, and poor appetite in the 2-week group was lower than that in the 3-week group.

CONCLUSION:

The clinical efficacy of nab-PTX in the 2-week and dose intensive 3 week did not show significant difference, but the 2-week treatment group had better tolerance and safety.

2026-12-31·ANNALS OF MEDICINE

Comparative effectiveness of percutaneous coronary intervention strategies for coronary small-vessel disease: a network meta-analysis of randomized trials

Review

作者: Du, Zhiyan ; Xu, Yixin ; Wang, ZhiLong ; Fan, Chao ; Jiang, Zhihui ; Wu, Tingting ; Zheng, Yingying ; Lv, Mingming ; Pan, Ying ; Adilijiang, Adilai. ; Bai, Bingxin ; Xie, Xiang ; Deng, Changjiang

BACKGROUND:

Coronary small-vessel disease (SVD) remains challenging for percutaneous coronary intervention (PCI) because small lumens magnify restenosis and ischemic risk. Multiple devices are available, yet their comparative performance is uncertain. This study evaluated and ranked PCI strategies for SVD.

METHODS:

A systematic review and network meta-analysis was conducted in accordance with PRISMA. PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and Google Scholar were searched from inception to 15 August 2025. Eligible studies were English-language randomized controlled trials enrolling adults with angiographic SVD defined as reference vessel diameter ≤3.0 mm, comparing PCI strategies, and reporting target lesion revascularization (TLR), binary restenosis (BR), or myocardial infarction (MI). A frequentist random-effects network meta-analysis generated odds ratios (ORs) with 95% confidence intervals (CIs) and treatment rankings using the surface under the cumulative ranking curve (SUCRA).

RESULTS:

Thirty-nine trials including 14,503 patients met the criteria. For TLR (37 studies; 11,980 patients), the highest SUCRA values were observed with sirolimus-eluting stents (SES 90.1%), zotarolimus-eluting stents (ZES 83.9%), and everolimus-eluting stents (EES 82.2%). For BR (32; 6,468), SES, ZES, and paclitaxel-coated balloons (DCB-PTX) ranked highest (95.0%, 80.0%, and 78.3%). For MI (37; 11,602), SES, DCB-PTX, and ZES ranked highest (79.0%, 78.7%, and 68.5%). Representative effects showed SES reduced TLR versus bare-metal stents (BMS) (OR, 0.25; 95% CI, 0.15-0.43) and MI versus BMS (OR, 0.41; 95% CI, 0.21-0.79). Conventional approaches such as BMS, plain old balloon angioplasty (POBA), and gold-plated balloon angioplasty (GPBA) ranked lowest across outcomes.

CONCLUSION:

SES provides the most consistent clinical benefit for coronary SVD. ZES, EES, and DCB-PTX are effective alternatives in selected settings, whereas BMS, POBA, and GPBA are less effective. These findings offer comparative evidence to guide device selection in SVD.

2026-12-31·OncoImmunology

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma

Article

作者: Cocolakis, Eftihia ; Cailhier, Jean-François ; Lapointe, Réjean ; Thébault, Paméla ; Shechtman, Yelena ; Lepage, Stéphanie ; Letendre, Caroline ; Le, Huy ; Dionne, Jeanne ; Bélanger, Karl ; Jamal, Rahima ; Lambert, Caroline ; Miller Jr, Wilson H.

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treated with pembrolizumab and CP. Peripheral blood was collected at baseline and after 2 cycles to characterize systemic immune activity by multiplex assays and flow cytometry. Seventy percent of patients received all 4 cycles of CP; 87% received pembrolizumab for 2 y or until progression. Grade 3 and higher adverse events (AEs) occurred in 50% of the patients. The overall response rate (ORR) and disease control rate (DCR) by irRC criteria were 43% and 53%, respectively. Median overall survival (OS) was 23.8 months. Objective response was associated with a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline, along with a larger proportion of mature NK cells and of CD4 T cells expressing BTLA or LAIR-1. Survival rate was higher for patients with lower baseline of IL-6, IL-8, and CD4⁺CD39⁺ T cells. Following treatment, pro-inflammatory soluble factors increased in both responders and non-responders. Addition of CP to pembrolizumab in this study did not appear to result in a response or survival advantage and was less tolerable than immunotherapy alone. Correlative data point to peripheral signals to investigate further as potential biomarkers. Trial registration: clinicaltrials.gov, NCT02617849, registered on December 1st, 2015.

5,918

项与紫杉醇相关的新闻（医药）

2026-04-29

·科兴制药

科兴制药出海产品白蛋白紫杉醇获阿联酋上市批准

近日，公司出海抗肿瘤产品——注射用紫杉醇（白蛋白结合型）（商品名：Apexelsin®），正式获得阿联酋药品管理局（Emirates Drug Establishment，EDE）上市批准，进入中东核心医药市场。阿联酋是中东地区经济最具活力的国家之一，Statista数据显示，2023年阿联酋国内生产总值高达4565.6亿美元，人均GDP达到了近4.7万美元，属高收入国家。同时，IQVIA的相关报告也显示，阿联酋医药市场规模及增长率近年持续向上，位居中东和非洲地区第二。有研究报告显示，乳腺癌占阿联酋所有癌症病例的25%，占阿联酋女性癌症病例的43%，也是女性癌症相关死亡的第二大原因。白蛋白紫杉醇是欧洲医学肿瘤学会（ESMO）指南推荐用于治疗乳腺癌、非小细胞肺癌及转移性胰腺癌等多种实体瘤的一线用药。此次Apexelsin®的获批，将为阿联酋肿瘤患者提供更多治疗选择。注射用紫杉醇（白蛋白结合型）剂型具备临床用药优势，相对普通紫杉醇注射液和紫杉醇脂质体，安全性和患者依从性有所提升，临床认可度较高，在肿瘤治疗领域具有不可或缺的临床价值。作为科兴制药的重磅出海产品，Apexelsin®于2024年取得欧盟委员会上市批准，随后相继在英国、秘鲁、乌拉圭、阿根廷、阿曼、马来西亚、中国澳门、格鲁吉亚、多米尼加、菲律宾等超30个国家和地区获批上市，已形成覆盖欧盟、拉美、东南亚及中东地区的全球化销售网络。欧盟高标准认证体系的背书，也有力推动了Apexelsin®在新兴市场的准入。未来，公司将继续深耕海外市场，推动更多高质量药品走向国际，造福更多患者。关于科兴制药科兴制药（股票代码：688136）是一家专注于重组蛋白、多功能抗体、靶向递送疗法等研发、生产、销售一体化的创新型国际化生物制药企业。聚焦抗肿瘤、自身免疫、抗病毒等治疗领域，围绕未被满足的临床需求，打造新型蛋白、新型抗体、核酸药物等前沿生物技术平台，开发精准治疗及新型靶向递送药物，坚持“创新+国际化”双轮驱动的平台型发展模式，致力于成为高品质生物药领导者，服务全球患者。公司核心产品稳居国内同类品种前列，覆盖全国各省市地区约20000家终端，其中等级医院约8000家，已通过欧盟、巴西、菲律宾、印度尼西亚等全球70多个国家的市场准入并实现销售。推荐阅读 *深度 | 药企国际化绕不开的话题：印度制药业 *创新高，2025年欧盟医药贸易顺差2205亿欧元 *二型糖尿病药物研发趋势及相关靶点解析

上市批准核酸药物

2026-04-28

·Business Wire

Genexine’s First-in-Class SOX2 Degrader GX-BP1 Demonstrates Up to 96% TGI and Eliminates Tumor Regrowth in Preclinical Models

SEOUL, South Korea--(BUSINESS WIRE)--Genexine, Inc. (KOSDAQ: 095700), a clinical-stage biotechnology company, today announced new preclinical data for its SOX2-targeting bioPROTAC candidate, GX-BP1, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. GX-BP1 is a first-in-class bioPROTAC drug candidate designed to selectively degrade SOX2, a transcription factor widely recognized as a key driver of tumor progression, cancer stemness, and therapeutic resistance, yet historically considered undruggable. By directly eliminating SOX2 via the ubiquitin-proteasome system, GX-BP1 targets a central driver of tumor relapse, metastasis, and resistance to standard therapies. Preclinical data demonstrated strong anti-tumor activity across multiple models. GX-BP1 monotherapy achieved approximately 70% tumor growth inhibition (TGI), confirming meaningful standalone efficacy. In combination settings, GX-BP1 restored sensitivity in chemotherapy-resistant models and enhanced the efficacy of EGFR-targeted therapies, including osimertinib, by suppressing SOX2-driven resistance mechanisms. Notably, the combination of GX-BP1 with carboplatin and paclitaxel showed a clear dose-dependent response, achieving 87% to 96% TGI, with near-complete tumor growth suppression at higher doses. In addition, while tumor regrowth was observed in the osimertinib monotherapy group, the combination of GX-BP1 with osimertinib completely prevented tumor relapse, accompanied by effective elimination of cancer stem cell populations. These findings position GX-BP1 as a potential backbone therapy for combination strategies, with broad applicability across chemotherapy, targeted therapy, and immunotherapy settings, particularly in resistant or refractory disease. Genexine has also established a clinically relevant delivery approach using a lung-targeted lipid nanoparticle (LNP) system, enabling efficient systemic delivery of over 70% GX-BP1 mRNA to lung tissues within 24 hours. GX-BP1 has demonstrated a comprehensive preclinical profile, including in vivo efficacy, pharmacokinetics, biodistribution, and safety, supporting advancement into IND-enabling studies. Genexine is actively pursuing global licensing and strategic partnership opportunities for GX-BP1 and its bioPROTAC platform-based pipelines. “GX-BP1 represents a differentiated therapeutic approach that directly targets a central driver of cancer resistance,” said Jaehyun Choi, Ph.D., Chief Executive Officer and Head of R&D at Genexine. “We believe its strong combination potential, and GX-BP1’s robust preclinical profile position it as a promising next-generation therapeutic candidate, and we are advancing discussions with global partners.” About Genexine Genexine is one of the first-generation biotechnology companies in South Korea, dedicated to developing innovative biologics to address unmet medical needs in patients with serious diseases. The company leverages its proprietary technology platforms, including the long-acting hyFc® platform, DNA vaccine technology, and the next-generation bioPROTAC platform, to develop novel therapeutics. In particular, Genexine is advancing a pipeline of global first-in-class drug candidates based on its bioPROTAC platform, including GX-BP1 for lung cancer and GX-BP2 for atopic dermatitis. In addition, the company is progressing late-stage bio-better assets toward commercialization. Efesa® (GX-E4), a long-acting treatment for anemia in chronic kidney disease, is currently under regulatory review in Korea and other global markets for non-dialysis patients. GX-H9, a long-acting growth hormone, is also preparing for regulatory approval in China. About EPDeg™ bioPROTAC EPDeg™ bioPROTAC is a next-generation targeted protein degradation (TPD) technology that directly fuses a synthetic nanobody-based target-binding moiety with an E3 ligase. This design overcomes key limitations of conventional small molecule-based PROTAC approaches, enabling improved development efficiency and enhanced tissue specificity. By selectively degrading disease-causing proteins, EPDeg™ bioPROTAC offers a novel therapeutic strategy with the potential to address previously undruggable targets.

2026-04-28

·今日头条

海和药物冲刺A股，三款创新药填补全球空白，甲磺酸瑞索利塞片成全球首个靶向治疗药物

上海海和药物研究开发股份有限公司近日披露首次公开发行股票并上市辅导工作总结报告，本次辅导由国金证券担任辅导机构，表明公司已完成A股申报的前期规范工作。海和药物成立于2011年，专注创新药研发、生产及商业化，连续多年被评为国家高新技术企业，并入选国家级专精特新“小巨人”企业。海和药物目前拥有3款已上市产品，其中多款填补了细分市场空白。2026年在日本获批上市的甲磺酸瑞索利塞片，是全球首个针对化疗后疾病进展且携带PIK3CA基因突变的卵巢透明细胞癌的单药靶向治疗药物，也是全球首个在日本获批的PI3Kα选择性抑制剂。该产品同时拓展至儿童用药领域，获国家药品监督管理局药品审评中心邀请进入“儿童抗肿瘤药物研发鼓励试点计划（星光计划）”，并作为国内在PIK3CA相关脉管畸形及过度生长谱疾病领域的首个治疗药物，填补了相关药物治疗方案空白。公司另两款上市产品同样具备差异化优势。谷美替尼片于2023年在国内获批上市，是国内首个获批的针对MET ex14跳跃突变的非小细胞肺癌一线药物；2024年在日本获批上市，成为我国首个在日本独立申请并获批的中国创新药，且已纳入中日两国医保目录。紫杉醇口服溶液是全球唯一获批上市的口服紫杉醇药物。在研管线方面，艾普美妥司他片已获国家药品监督管理局药品审评中心优先审评，用于治疗不可手术的局部晚期或转移性经治上皮样肉瘤，是国产首款获得新药上市申请受理的EZH1/2双靶小分子抑制剂。PARP1选择性抑制剂HH101785也已获得临床试验批准。市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。本文源自：市场资讯作者：观察君

100 项与紫杉醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00491	紫杉醇	L01CD01	DB01229

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
晚期胃癌	中国	DAE HWA PHARM Co., Ltd.	2024-09-19
晚期胃癌	中国	上海海和药物研究开发股份有限公司	2024-09-19
转移性胰腺腺癌	欧盟	Accord Healthcare SL	2024-01-05
转移性胰腺腺癌	冰岛	Accord Healthcare SL	2024-01-05
转移性胰腺腺癌	列支敦士登	Accord Healthcare SL	2024-01-05
转移性胰腺腺癌	挪威	Accord Healthcare SL	2024-01-05
铂类耐药性原发性腹膜癌	欧盟	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	冰岛	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	列支敦士登	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	挪威	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	欧盟	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	冰岛	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	列支敦士登	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	挪威	Inceptua SA	2018-11-20
铂敏感性输卵管癌	欧盟	Inceptua SA	2018-11-20
铂敏感性输卵管癌	冰岛	Inceptua SA	2018-11-20
铂敏感性输卵管癌	列支敦士登	Inceptua SA	2018-11-20
铂敏感性输卵管癌	挪威	Inceptua SA	2018-11-20
生殖细胞瘤	日本	Clinigen KK	2013-02-21
生殖细胞瘤	日本	Bristol Myers Squibb Co.	2013-02-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	申请上市	欧盟	Accord Healthcare SL	2023-11-09
转移性胰腺癌	临床3期	中国	上海谊众药业股份有限公司	2025-01-21
高级别胶质瘤	临床3期	中国	浙江大学	2024-04-01
HEGF2阴性乳腺癌	临床3期	中国	上海谊众药业股份有限公司	2023-09-25
皮肤鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
下咽癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
转移性头颈部鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
下咽部鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
喉鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
口腔鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03326102 (OPERA, Pubmed \| Breast Cancer Res Treat)	临床2期	复发性HER2阴性乳腺癌 HER2-negative	72	DHP107	艱願簾醖網襯醖夢憲製(鑰襯膚觸範糧淵蓋遞憲) = 網積醖獵蓋繭選窪鏇鑰鬱獵憲積遞膚製鹹憲窪 (簾餘選鑰鹽廠餘襯選壓, 15.1 ~ 37.3) 更多	相似	2026-05-01
				IV paclitaxel	艱願簾醖網襯醖夢憲製(鑰襯膚觸範糧淵蓋遞憲) = 積醖構衊構繭艱選蓋鏇鬱獵憲積遞膚製鹹憲窪 (簾餘選鑰鹽廠餘襯選壓, 13.2 ~ 48.7) 更多
NCT01507428 (CTgov)	临床2期	非小细胞肺癌IIIA期 \| 非小细胞肺癌IIIB期 \| 局部晚期非小细胞肺癌	138	External Beam Radiation Therapy+18F-Fluoromisonidazole+Fludeoxyglucose F-18+Carboplatin+Paclitaxel (Arm I (Standard Chemoradiotherapy))	齋鑰顧壓鹽壓餘齋鹽鹹(醖範衊顧顧構醖築願鹽) = 願鏇獵積壓糧壓鹽艱艱鹽糧壓艱衊製餘鑰遞遞 (範鬱願糧醖齋鹽築窪艱, 0.17) 更多	-	2026-04-21
				Computed Tomography+18F-Fluoromisonidazole+Fludeoxyglucose F-18+Carboplatin+Paclitaxel (Arm II (Experimental Chemoradiotherapy))	齋鑰顧壓鹽壓餘齋鹽鹹(醖範衊顧顧構醖築願鹽) = 鹽觸衊廠選製夢觸窪顧鹽糧壓艱衊製餘鑰遞遞 (範鬱願糧醖齋鹽築窪艱, 0.39) 更多
NCT02654119 (CTgov)	临床2期	HER2阳性乳腺癌	20	Laboratory Biomarker Analysis+Trastuzumab+Cyclophosphamide+Paclitaxel	壓蓋艱觸鬱願鑰鹹願衊 = 觸襯繭願醖廠顧艱觸壓淵衊糧憲艱製鬱膚壓襯 (製艱鹽獵艱顧鏇築範鏇, 鏇願簾築膚齋積憲醖範 ~ 鬱餘積壓艱遞鏇壓衊積) 更多	-	2026-03-23
NCT03315364 (OPTIMAL, Pubmed) 人工标引	临床3期	转移性HER2阴性乳腺癌 \| 复发性HER2阴性乳腺癌 HER2 Negative	549	DHP107	鬱窪顧觸鑰鏇衊願鏇窪(淵觸鏇夢鏇淵鏇繭鑰憲) = 範觸遞鹽蓋製廠製積壓觸艱構齋蓋顧鏇廠鏇糧 (鑰淵膚繭壓築糧餘繭鹹 ) 更多	非劣	2026-03-13
				Paclitaxel	鬱窪顧觸鑰鏇衊願鏇窪(淵觸鏇夢鏇淵鏇繭鑰憲) = 選鹽顧遞積鹹廠艱憲鹽觸艱構齋蓋顧鏇廠鏇糧 (鑰淵膚繭壓築糧餘繭鹹 ) 更多
NCT03179904 (CTgov)	临床2期	HER2阳性乳腺癌 \| HER2阳性转移性乳腺癌 \| 晚期乳腺癌	17	trastuzumab+FASN inhibitor TVB-2640+paclitaxel (Cohort A)	築襯鹽積衊襯繭壓顧製 = 餘簾選觸齋遞鏇壓鑰蓋選鹹齋夢鬱網製製淵鬱 (鑰廠餘繭襯膚壓鑰網壓, 襯餘鹹憲網壓顧鬱網鹽 ~ 願網網網醖構鬱淵繭遞) 更多	-	2026-02-24
				trastuzumab+FASN inhibitor TVB-2640+fulvestrant+letrozole+paclitaxel+exemestane+anastrozole (Cohort B)	築襯鹽積衊襯繭壓顧製 = 選鹽選遞窪糧簾鹹糧願選鹹齋夢鬱網製製淵鬱 (鑰廠餘繭襯膚壓鑰網壓, 廠獵餘鬱蓋製鹹選範簾 ~ 壓遞膚顧蓋製鏇憲鹹醖) 更多
NCT03101748 (CTgov)	临床1/2期	炎症性乳腺肿瘤 \| 乳腺癌 \| 局部晚期乳腺癌 ... 更多	34	trastuzumab+neratinib+paclitaxel+pertuzumab (Cohort 1 Phase Ib Dose Level 0)	鏇淵網淵選窪選窪鹹膚 = 壓築製淵簾鑰醖蓋願衊齋蓋鬱襯齋顧襯衊選餘 (壓鏇衊願鹹淵襯獵襯艱, 鑰網淵遞網鑰衊獵窪蓋 ~ 醖願醖淵觸鹹襯顧遞淵) 更多	-	2026-02-12
				trastuzumab+neratinib+paclitaxel+pertuzumab (Cohort 1 Phase Ib Dose Level 1)	鏇淵網淵選窪選窪鹹膚 = 鑰繭憲鏇範鬱積積顧鬱齋蓋鬱襯齋顧襯衊選餘 (壓鏇衊願鹹淵襯獵襯艱, 鑰夢襯簾遞網製糧鹹廠 ~ 齋餘顧選壓襯網糧廠憲) 更多
NCT03829722 (CTgov)	临床2期	口咽部鳞状细胞癌 \| 人乳头瘤病毒相关的头颈部肿瘤	26	Radiation Therapy+Nivolumab+Carboplatin+Paclitaxel	壓鹽醖選襯選窪觸衊鑰 = 繭廠襯艱膚構顧艱衊範築襯鏇簾鬱齋築顧廠鏇 (鑰糧齋構選蓋衊廠壓範, 鹽鑰壓網構齋廠夢鏇鑰 ~ 鹹網願蓋糧範壓觸構觸) 更多	-	2026-01-22
NCT04770272 (neoMono, CTgov)	临床2期	三阴性乳腺癌	442	Biopsy Arm A+Cyclophosphamide+Carboplatin+Paclitaxel+Atezolizumab 840 MG in 14 ML Injection+epirubicin (Arm A)	糧鏇壓網鹽夢齋襯繭構 = 淵蓋淵築製鑰簾齋築鏇糧遞蓋鹹積襯鹹憲選鑰 (衊觸築淵選鹹糧構餘鹹, 鏇廠鏇廠淵襯範選積鹹 ~ 顧鹽選積壓遞構蓋鏇膚) 更多	-	2026-01-12
				Biopsy Arm B+Cyclophosphamide+Carboplatin+Paclitaxel+Atezolizumab 1200 MG in 20 ML Injection+epirubicin (Arm B)	糧鏇壓網鹽夢齋襯繭構 = 獵獵範顧窪範窪蓋鏇艱糧遞蓋鹹積襯鹹憲選鑰 (衊觸築淵選鹹糧構餘鹹, 簾齋簾襯憲鬱衊鑰膚壓 ~ 鏇觸鹹糧簾憲醖壓鑰壓) 更多
NCT02931890 (CRITICS-II, ASCO_GI2026 \| NEWS) 人工标引	临床2期	胃癌新辅助	201	docetaxel+oxaliplatin+capecitabine	艱淵簾醖夢艱鑰壓齋壓(鹽網廠蓋繭選鏇鬱顧壓) = 窪鑰淵蓋餘蓋窪鏇蓋膚繭網觸鏇遞築顧艱鑰齋 (範簾簾製襯糧壓襯鏇齋, 58 ~ 80) 更多	积极	2026-01-08
				docetaxel+oxaliplatin+capecitabine+45Gy/25 fractions + paclitaxel or carboplatin	艱淵簾醖夢艱鑰壓齋壓(鹽網廠蓋繭選鏇鬱顧壓) = 襯糧餘簾鹹蓋齋艱獵鏇繭網觸鏇遞築顧艱鑰齋 (範簾簾製襯糧壓襯鏇齋, 75 ~ 94) 更多
NCT04762953 (STOPGAP, ASCO_GI2026)	临床2期	腹膜癌巩固	31	IP PTX + systemic therapy	顧糧窪蓋膚齋鑰遞鬱餘(齋鬱範築觸願壓築糧繭) = 醖憲鹹醖膚醖夢膚顧夢淵鹽繭製鑰糧鹹膚網醖 (鏇壓鑰膚艱遞網願製醖 ) 更多	积极	2026-01-08